FRANKLIN LAKES, N.J. and
SIZIANO, Italy, Sept. 20, 2017 /PRNewswire/ -- BD (Becton,
Dickinson and Company) (NYSE: BDX), a leading global medical
technology company, and Euroclone (Euroclone Diagnostica Srl) today
announced a development and global distribution agreement for
molecular tests to detect emerging sexually-transmitted
pathogens.
According to the World Health Organization, more than 1 million
sexually transmitted infections (STIs) are acquired each day, with
the increasing prevalence of drug resistance posing a significant
threat to reducing the effectiveness of STI
treatment.1
The molecular assays in development will offer an increased
likelihood of patients receiving proper diagnoses and therapy
whether or not they are exhibiting symptoms. The new assays will
also support clinical laboratories in antimicrobial stewardship
efforts and assist institutions in complying with European STI
screening guidelines.2,3
By using the fully-automated BD MAX™ System, the collaborative
solutions will detect infectious genital mycoplasmas, including
Mycoplasma and Ureaplasma species. These specific
pathogens are difficult to identify by conventional
methods,2,3 and if not diagnosed and treated
appropriately, place infected individuals at risk for immediate and
long-term health consequences, such as infertility and increased
susceptibility to HIV2,4. The assays will also identify
resistance markers of common drug therapies, including macrolides,
a class of antibiotics often used as first-line treatment for STIs,
which enables physicians to prescribe an appropriate course of
antibiotic therapy.
"There is growing concern worldwide for macrolide resistance in
Mycoplasma genitalium and more recent reports that have
indicated increasingly prevalent quinolone resistance are
worrying," commented Dr. Suneeta
Soni, consultant in Sexual Health and HIV, Brighton, United Kingdom.
BD is a global leader in providing solutions for women's health
and STIs. With the addition of these assays to the existing BD MAX
portfolio, in conjunction with BD SurePath™, a liquid-based
Pap test, and the BD Onclarity™ HPV assay*, a molecular test for
the detection of 14 high-risk HPV genotypes, BD continues to
enhance its comprehensive solutions that enable clinical
laboratories to address evolving diagnostic needs and regional
guidelines2,3, and help mitigate the threat of
antimicrobial resistance.5
"BD and Euroclone share a passion for reducing the risks
associated with undiagnosed STIs, as well as the burden of symptoms
that impact the lives of many worldwide," said Doug White, vice president of Women's Health
& Molecular Diagnostics for BD.
"Our collaboration with BD is a very important and strategic
path for the future of Euroclone. It brings us great satisfaction
to work together to address the emerging threat of genital
mycoplasmas," said Franco Aiolfi, chief executive officer of
Euroclone SpA and Euroclone Diagnostica Srl.
BD and Euroclone plan to develop and commercialize the assays
for launch outside of the U.S. beginning in 2018 and in the U.S. at
a later date.
*This product is not for sale in the U.S.
About BD
BD is a global medical technology company
that is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. BD leads in
patient and healthcare worker safety and the technologies that
enable medical research and clinical laboratories. The company
provides innovative solutions that help advance medical research
and genomics, enhance the diagnosis of infectious disease and
cancer, improve medication management, promote infection
prevention, equip surgical and interventional procedures, and
support the management of diabetes. The company partners with
organizations around the world to address some of the most
challenging global health issues. BD has nearly 50,000 associates
across 50 countries who work in close collaboration with customers
and partners to help enhance outcomes, lower healthcare delivery
costs, increase efficiencies, improve healthcare safety and expand
access to health. For more information on BD, please visit
bd.com.
About Euroclone Diagnostica Srl
Euroclone Diagnostica
Srl (http://www.euroclonediagnostica.it) is a subsidiary of
Euroclone S.p.A. headquartered in Siziano, Italy with a focus on the development,
production and commercialization of innovative diagnostics,
particularly in the area of molecular biology. Euroclone
Diagnostica Srl operates regionally and internationally, supporting
products in the areas of genetics diagnostics, diagnostics
infectivity, oncology, nucleic acid extraction and drugs of
abuse.
---
1Sexually transmitted infections (STIs). (2016, August).
Retrieved June 14, 2017, from
http://www.who.int/mediacentre/factsheets/fs110/en/
2Jensen, J. S., et al. (2016). 2016 European guideline
on Mycoplasma genitalium infections (H. Moi, Ed.). Journal
of the European Academy of Dematology and Venereology.
doi:10.1111/jdv.13849
3Horner, P. J., Blee, K., & Van der Meijden, W. (2016). 2016 European
guideline on the management of non-gonococcal urethritis. (H. Moi,
Ed.). International Journal of STD & Aids, 27(11),
928-937. doi:10.1177/0956462416648585
4Ona, S., Molina, R. L., & Diouf, K. (2016).
Mycoplasma genitalium: An Overlooked Sexually Transmitted Pathogen
in Women? (L. Hafner, Ed.). Infectious Diseases in Obstetrics
and Gynecology, 2016(4513089), 1-9.
http://dx.doi.org/10.1155/2016/4513089
5Soni S, et al. Sex Transm Infect
2017;0:1–2. doi:10.1136/sextrans-2016-053077
BD
Contacts:
|
|
|
|
Gwen
Gordon
|
Monique N.
Dolecki
|
BD Public
Relations
|
BD Investor
Relations
|
858.812.3724
|
201.847.5378
|
Gwen.Gordon@bd.com
|
Monique.Dolecki@bd.com
|
|
|
Euroclone
Contact:
|
|
|
|
Fabio
Bolchi
|
|
Euroclone
Communications & Public Relations
|
|
+39.02.38195331
|
|
f.bolchi@euroclone.it
|
|
View original
content:http://www.prnewswire.com/news-releases/bd-and-euroclone-announce-development-and-global-distribution-agreement-for-tests-to-detect-emerging-sexually-transmitted-pathogens-300522421.html
SOURCE BD (Becton, Dickinson and Company)